On Friday, Resonant Inc (NASDAQ:RESN)’s shares declined -0.45% to $4.44, while its weekly performance remained poor, showing the downward trend up to -39.92%, on April 2, Resonant Inc (RESN), offered an update on the relationship with and first design project for its first customer.
In February, Resonant administrations talk about the transition of its relationship with its first customer from development to commercialization. This week, Resonant received notice that the development contract with its first customer has been terminated, and that Resonant must pursue commercialization of its designs with this customer by working directly with the filter manufacturer. Resonant intends to collaborate with the filter manufacturer to continue to submit improved product designs for consideration by this customer for insertion into its product modules.
Terry Lingren, Chairman, Co-Founder and CEO of Resonant, stated, “The Development Contract has accomplished a principal purpose – to enable Resonant to develop a beyond-state-of-the-art filter design capability. This was only possible through sustained commitment from our first customer over the past several years. While the probability has been reduced that our design will be selected for the customer’s original target product, we believe that the design for the band that we developed for the original product could be considered by this customer for use in next generation, follow-on modules. Additionally, as a result of the customer’s termination of our development contract, we are now permitted to market the design for the same band to other potential customers.
Resonant Inc., a late-stage development corporation, develops filter designs for radio frequency (RF) front-ends used in the mobile device industry. The corporation uses Infinite Synthesized Networks technology to configure and connect resonators, the building blocks of RF filters.
Ocular Therapeutix Inc (NASDAQ:OCUL)’s shares dropped -5.43% to $26.99, during the last trading session on Friday, while its weekly performance remained poor, showing the downward trend up to -33.99%, after Ocular Therapeutix Inc (OCUL), declared topline data from the Corporation’s second of two Phase 3 clinical trials evaluating the safety and efficacy of its lead product candidate, OTX-DP (Sustained Release Dexamethasone, 0.4mg), for the treatment of ocular inflammation and pain following cataract surgery and stated additional details from the first Phase 3 clinical trial. The two primary efficacy endpoints for the OTX-DP Phase 3 clinical trials were statistically noteworthy differences between the treatment group and the placebo group for the absence of pain on day 8 and absence of inflammatory cells on day 14. Both endpoints need to be met for the trials to be considered successful. In the second Phase 3 clinical trial, OTX-DP met one of the study’s two primary efficacy endpoints. In this trial, 77.5% of patients receiving OTX-DP stated an absence of pain in the study eye on day 8 following insertion of the drug product, contrast to 58.8% of those receiving placebo vehicle control punctum plug, a difference which was statistically noteworthy(p=0.0025). 39.4% of OTX-DP-treated patients showed an absence of inflammatory cells in the anterior chamber of the study eye on day 14 following drug product insertion, contrast to 31.3% of those receiving placebo vehicle control punctum plug , a difference which was not statistically noteworthy(p=0.2182). Additionally, there were a total of 240 patients enrolled in the second clinical trial, with a 2:1 randomization of treated and control patients.
Ocular Therapeutix, Inc., a biopharmaceutical corporation, focuses on the development and commercialization of therapies for eye diseases and conditions using its proprietary hydrogel platform technology in the United States. It markets ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions during cataract surgery.
At the end of Friday’s trade, Nymox Pharmaceutical Corporation (NASDAQ:NYMX)‘s shares raised 2.56% to $1.20, while its weekly performance remained poor, showing the downward trend up to -30.64%, on April 1, Nymox Pharmaceutical Corporation (NYMX), declared that the Corporation is undertaking further analyses of its pivotal U.S. Phase 3 studies of NX-1207 for prostate enlargement (BPH). This will comprise new long-term data from Studies NX02-0017 and NX02-0018. The Corporation anticipates to provide these new pivotal Phase 3 study results in Q2 or early Q3 this year.
Dr. Paul Averback, CEO of Nymox said, “Despite the setback of top-line results not initially beating controls statistically at 12 months post-treatment in these large studies, we continue to believe that NX-1207 has enormous potential for long-term administration of BPH. Additional new blinded protocol data from the same pivotal studies is being prospectively captured in order to assess long-term results in patients up to 5 years after a single injection of NX-1207 2.5 mg vs placebo.”
Nymox Pharmaceutical Corporation, a biopharmaceutical corporation, is engaged in the research and development of products for the aging population. It provides NicAlert and TobacAlert products that use urine or saliva to detect use of and exposure to tobacco products, in addition to AlzheimAlert, a proprietary urine assay that aid physicians in the diagnosis of Alzheimer’s disease.
Great Basin Scientific Inc (NASDAQ:GBSN), ended its Friday’s trading session with -8.98% loss, and closed at $2.94, while its weekly performance remained poor, showing the downward trend up to -29.50%, after Great Basin Scientific Inc (GBSN), declared that co-founder and CEO Ryan Ashton will present at the 2nd Annual Growth Capital Expo at 2:00 p.m. PDT April 13 at Caesars Palace in Las Vegas, NV. Administration will also be accessible for investor meetings on April 13 and 14.
Great Basin Scientific, Inc., a molecular diagnostic testing corporation, doing business as Great Basin Corporation, develops and commercializes molecular diagnostic systems that are designed to test hospital-attained infections. The corporation’s platform provides C. diff test, a rapid medical diagnostic test for the detection of C. diff, a gram-positive bacteria that causes severe diarrhea and other intestinal disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
